Stellate Ganglion Block and Prognosis of Neurological Function After Subarachnoid Hemorrhage

NCT07652749 | Not Yet Recruiting

• 1 other identifier: Z191100006619069
• Study Type: interventional
• Target: 560
• Locations: 1 country
• Sites: 1

Brief Summary

The incidence of cerebral vasospasm after aneurysm subarachnoid hemorrhage (aSAH) is as high as 70%; cerebral vasospasm（CVS） is closely related to delayed cerebral ischemia （DCI）, which is one of the important reasons for poor outcomes in patients with aSAH. In recent years, it has been reported that stellate ganglion block(SGB) can effectively alleviate cerebral vasospasm(CVS), reduce cerebral blood flow velocity and increase cerebral perfusion in patients with aneurysm subarachnoid hemorrhage(aSAH)。However, whether the alleviation of CVS after SGB is beneficial to the long-term neurological prognosis has not been confirmed Therefore, a prospective randomized controlled study is needed to further explore the role of SGB block in improving the outcomes of patients with aSAH.

Conditions

Aneurysmal Subarachnoid Hemorrhage; Stellate Ganglion Block; Neurological Prognosis

Outcome Measures

Primary Outcomes (1)

• The modified Rankin Scale (mRS) scores at 90 days

  The modified Rankin Scale (mRS) is used to evaluate the primary outcome. The scale of mRS is 0 to 6. The best neurological outcome is the mRS with 0, indicating no any symptom left. mRS of 6 is the worst, indicating death. mRS will be evaluated by outcomes assessor who is blinded to the grouping.

  90 days postoperatively

Secondary Outcomes (4)

• The incidence of delayed cerebral ischemia (DCI) during hospitalization

  At discharge, an average of 2 weeks

• All cause mortality during 90 days after onset

  90 days postoperatively

• Length of stay in the intensive care unit and hosipital

  At discharge, an average of two weeks

• Adverse events during hospitalization

  At discharge, an average of 2 weeks

Study Arms (2)

Intervention group

EXPERIMENTAL

In addition to routine anesthesia management and surgical operations, an ultrasound-guided stellate ganglion block was performed once prior to the initiation of surgery, and then receive standard care after operation. Related statistical indicators were collected prospectively.

Procedure: Intervention group

Blank control group

NO INTERVENTION

In this study, a blank control was used. Routine anesthesia management and surgical operation were used without any special interventions, and then receive standard care after operation. Only relevant statistical indicators were collected prospectively.

Interventions

Intervention group PROCEDURE

Prior to the initiation of surgery, a single ultrasound-guided stellate ganglion block was performed on the ipsilateral side of the lesion.The dose and concentration of local anesthesia: 0.5% ropivacaine 5-10ml. Criteria for successful block: the patient developed Horner's syndrome, characterized by miosis, ptosis, eyeball caved in, nasal congestion, conjunctival congestion, reddish face and no sweat on the face

Also known as: Stellate ganglion block

Intervention group

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age range: 18-65 years old;
• Within 72 hours after onset of aSAH,and planning surgical treatment(aneurysm embolizing or clipping);
• Preoperative Hunt-Hess grade 2-3
• Sign informed consent.

You may not qualify if:

• ASA \> grade IV;
• Patients with posterior circulation aneurysm;
• Patients with severe systemic hemorrhagic diseases;
• Patients with trauma and local infection in the nerve block area;
• Local anatomic structure changes (neck structure changes caused by radiotherapy, chemotherapy and surgery);
• Allergy to known local anesthetics;
• Pregnant and lactating women.

Sponsors & Collaborators

• Beijing Tiantan Hospital: lead

Study Sites (1)

Beijing Tiantan Hospital, Capital Medical University

Beijing, Beijing Municipality, 100070, China

Location

MeSH Terms

Conditions

Subarachnoid Hemorrhage

Condition Hierarchy (Ancestors)

Intracranial Hemorrhages; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Ruquan Han, M.D., Ph.D

  Beijing Tiantan Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ruquan Han, M.D., Ph.D

CONTACT

8610-59976660; ruquan.han@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: March 2, 2021
• First Posted: June 17, 2026
• Study Start: June 15, 2026
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): March 31, 2029
• Last Updated: June 17, 2026

Record last verified: 2026-06

Locations

CN (1)